Observational analysis shows low hemorrhagic risk with triple therapy in acute ischemic stroke patients, highlighting its potential as an alternative when EVT is not feasible.
Background: Endovascular thrombectomy (EVT) has revolutionized acute ischemic stroke management but remains inaccessible to many patients due to anatomical, clinical, or logistical barriers. Treatment strategies for patients with intracranial occlusions who are ineligible for intravenous thrombolysis remain undefined. We evaluated the safety of short-term Triple Therapy (TT; heparin, aspirin, clopidogrel) in this population. Methods: We conducted a retrospective analysis of patients aged 1890 with symptom onset 24 hours, radiologically confirmed intracranial occlusion, NIHSS 10, and ineligibility for intravenous thrombolysis. Patients received either TT for 4872 hours or EVT (serving as controls). Primary outcomes included symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), extracranial hemorrhage, and 30-day mortality. Secondary outcomes included vessel recanalization, NIHSS change, ICU/hospital stay, and modified Rankin Scale (mRS) at 90 days. Results: Forty-seven patients met criteria (median age: 63 years; 43% female); 25 received TT, 22 underwent EVT. TT patients had lower baseline NIHSS (2.442.79 vs. 6.592.77; p<0.001). No sICH occurred with TT vs. 2 cases (9.1%) in EVT (p=0.20). ICH was observed in 8% (TT) vs. 27.3% (EVT) (p=0.11); extracranial hemorrhage rates were similar (4% vs. 4.5%). No 30-day mortality was reported. EVT achieved higher complete recanalization (77.3% vs. 28%; p<0.001), but clinical outcomes were comparable: mean NIHSS change (0.204.22 vs. 0.298.85; p=0.98) and discharge mRS (1.201.22 vs. 2.191.97; p=0.06). Conclusions: Short-term TT showed low hemorrhagic risk, including no sICH, and may offer a safe, accessible treatment alternative for select patients with intracranial occlusions ineligible for thrombolysis or EVT. Comparable clinical outcomes, despite lower recanalization rates, likely reflect the favorable baseline prognosis of TT patients.
No takes yet. Share an insight, caveat, or question.
Chaudhari et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: